Price T Rowe Associates Inc Repligen Corp Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Repligen Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,608,433 shares of RGEN stock, worth $673 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
4,608,433
Previous 3,568,316
29.15%
Holding current value
$673 Million
Previous $656 Million
11.48%
% of portfolio
0.07%
Previous 0.08%
Shares
15 transactions
Others Institutions Holding RGEN
# of Institutions
492Shares Held
53.7MCall Options Held
420KPut Options Held
85.3K-
Black Rock Inc. New York, NY7.57MShares$1.1 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.07MShares$739 Million0.01% of portfolio
-
State Street Corp Boston, MA1.74MShares$254 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA1.42MShares$207 Million0.55% of portfolio
-
Invesco Ltd. Atlanta, GA1.31MShares$191 Million0.04% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $8.1B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....